Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection.
JournalACG Case Reports Journal
PublisherWolters Kluwer Health
MetadataShow full item record
AbstractImmune checkpoint inhibitors such as nivolumab increase the T-cell destruction of malignancies but can also trigger a broad variety of immune-related adverse events (irAEs). Colitis as an irAE is well-documented, but upper gastrointestinal tract involvement is primarily unrecognized. We present a patient who developed gastritis as an irAE after multiple cycles of nivolumab and initially responded well to steroid therapy but then developed superimposed cytomegalovirus infection. The similarity between both presentations highlights the importance of having a broad differential diagnosis in patients with gastrointestinal complaints treated with immune checkpoint inhibitors and the need for further studies to better characterize gastritis as an irAE.
Rights/Terms© 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/18129
- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
- Authors: Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N
- Issue date: 2019 Oct 21
- An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
- Authors: Miyahara K, Noda T, Ito Y, Hidaka H, Fujimoto S, Takedomi H, Akutagawa T, Sakata Y, Shimamura T, Tominaga N, Yamaguchi D, Fujimoto K
- Issue date: 2020
- Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
- Authors: Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V
- Issue date: 2020 Jan
- Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
- Authors: Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y
- Issue date: 2018 Nov
- Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
- Authors: Zhang HC, Luo W, Wang Y
- Issue date: 2019 Feb 18